Clinical trials: AD-MCI, open to volunteers
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Alzheimer s Disease, Major Depressive Disorder (MDD)
VR Pupillometry in Cognitive Impairment
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important.
- Conditions
- Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
- Trial name
- NCT07402356
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Mild Cognitive Impairment, Alzheimer Disease
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
- Trial name
- Stress-AD (NCT05795634)
- Testing
- Trier Social Stress Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Johns Hopkins University
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
REAl World Dementia OUTcomes: Observational Study
READ-OUT observational study will investigate blood-based biomarkers for dementia in real-world clinical settings. This 3-year observational study will include 3165 people, males or females aged 45 years or older, with cognitive…
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia
- Trial name
- READ-OUT (NCT07238049)
- Where
- 27 sites in United Kingdom
- Volunteers
- 3,165 people
- Sponsor
- University of Oxford
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease, Cognitive Impairment
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
- Trial name
- NCT06245031
- Testing
- Sensory Stimulation System (GS120) - Active
- Where
- 53 sites in United States
- Volunteers
- 402 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer Disease (AD), Alzheimer Dementia
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively.
- Conditions
- Alzheimer Disease (AD), Alzheimer Dementia, Mild Cognitive Impairment (MCI)
- Trial name
- NCT07152418
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
MCI, Subjective Cognitive Decline (SCD)
FACE Phase II (a Stage II Trial)
How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD/ADRD) is understudied.
- Conditions
- MCI, Subjective Cognitive Decline (SCD), Mild Behavioral Impairment
- Trial name
- NCT07130669
- Testing
- Cognitive Remediation, Cognitive Remediation II
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Dementia, Mild Cognitive Impairment (MCI)
Comprehensive Assessment of Neurodegeneration and Dementia
This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits.
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD)
- Trial name
- COMPASS-ND (NCT03402919)
- Where
- 19 sites in Canada
- Volunteers
- 1,573 people, healthy volunteers welcome
- Sponsor
- McGill University
Alzheimer Disease (AD)
BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention
The BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) pilot study was launched at Parkwood Hospital in response to national calls for implementation of biomarker diagnostics in Canada.
- Trial name
- BioMIND 2 (NCT07422038)
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mild Cognitive Impairment, Alzheimer Dementia
Innate Immunity Stimulation Via TLR9 in Early AD
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD).
- Trial name
- NCT05606341
- Testing
- CpG1018
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Alzheimer Disease, Mild Alzheimer Disease
Repurposing Siponimod for Alzheimer's Disease
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects.
- Conditions
- Alzheimer Disease, Mild Alzheimer Disease, MCI With Increased Risk for Alzheimer Disease, Cognitive Impairment, Mild
- Trial name
- SIPO1-AD (NCT06639282)
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease
This project aims to longitudinally profile plasma-derived GDEVs and plasma biomarkers of neuroinflammation across three stages of the AD continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's…
- Conditions
- Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease Dementia, Alzheimer's Disease (AD)
- Trial name
- GLEVAD (NCT07803055)
- Testing
- blood sampling
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a…
- Trial name
- NCT07659964
- Testing
- Metronome
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Alzheimer Disease, Mild Cognitive Impairment
The Swedish BioFINDER - Preclinical AD Study
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT06121544
- Testing
- Plasma tau, Plasma β-Amyloid 42/40 (Aβ42/Aβ40), Flutemetamol F18 Injection
- Where
- Sweden
- Volunteers
- 800 people
- Sponsor
- Skane University Hospital
Mild Cognitive Impairment, Alzheimer's Disease(AD)
Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and…
- Trial name
- NCT07239310
- Testing
- Participants receive Neuclare Device while continuing their cognitive medication
- Where
- 7 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- Deepsonbio
Alzheimer, Cognitive Unimpaired
Brain Heath Service for Prevention of AD
The aim of the program to serve as a prototype for future preventive program for AD in the region. The program will recruit elderly participants.
- Conditions
- Alzheimer, Cognitive Unimpaired, Mild Cognitive Impairment
- Trial name
- BEAT AD (NCT07834528)
- Testing
- medical referral and/or educational programs
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Healthy
A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants
This trial is a randomized, double-blind, placebo-controlled, single- and multiple-oral administration, phase 1 clinical trial to investigate the safety, tolerability, and pharmacokinetics of AS-S603 in healthy Korean or…
- Trial name
- NCT06786676
- Testing
- AS-S603
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Amyloid Solution Inc